Advertisement

Letter to the editor: reply to Antonio Ieni “Intratumoral HER2 heterogeneity in early gastric carcinomas: potential bias in therapeutical management”

  • Kazuki Kanayama
  • Hiroshi ImaiEmail author
  • Eri Usugi
  • Taizo Shiraishi
  • Yoshifumi S. Hirokawa
  • Masatoshi Watanabe
Letter to the Editor
  • 31 Downloads

Notes

Authors contributions

Kazuki Kanayama: writing—original draft, writing–review and editing.

Hiroshi Imai: writing—review and editing.

Eri Usugi: writing—review and editing.

Taizo Shiraishi: writing—review and editing.

Yoshifumi S. Hirokawa: writing—original draft, writing—review and editing.

Masatoshi Watanabe: writing—review and editing.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflicts of interest.

References

  1. 1.
    Ieni A, Barresi V, Caltabiano R, Caleo A, Bonetti LR, Lanzafame S, Zeppa P, Caruso RA, Tuccari G (2014) Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis. Int J Mol Sci 15:22331–22341.  https://doi.org/10.3390/ijms151222331 CrossRefGoogle Scholar
  2. 2.
    Ieni A, Barresi V, Rigoli L, Caruso RA, Tuccari G (2015) HER2 status in premalignant, early, and advanced neoplastic lesions of the stomach. Dis Markers 2015:234851.  https://doi.org/10.1155/2015/234851 CrossRefGoogle Scholar
  3. 3.
    Kanayama K, Imai H, Usugi E, Shiraishi T, Hirokawa YS, Watanabe M (2018) Association of HER2 gene amplification and tumor progression in early gastric cancer. Virchows Arch 473:559–565.  https://doi.org/10.1007/s00428-018-2433-y CrossRefGoogle Scholar
  4. 4.
    Kanayama K, Imai H, Yoneda M, Hirokawa YS, Shiraishi T (2016) Significant intratumoral heterogeneity of human epidermal growth factor receptor 2 status in gastric cancer: a comparative study of immunohistochemistry, FISH, and dual-color in situ hybridization. Cancer Sci 107:536–542.  https://doi.org/10.1111/cas.12886 CrossRefGoogle Scholar
  5. 5.
    Yan Y, Lu L, Liu C, Li W, Liu T, Fu W (2015) HER2/neu over-expression predicts poor outcome in early gastric cancer without lymph node metastasis. Clin Res Hepatol Gastroenterol 39:121–126.  https://doi.org/10.1016/j.clinre.2014.06.019 CrossRefGoogle Scholar
  6. 6.
    Cao L, Hu X, Zhang Y, Huang G (2011) Adverse prognosis of clustered-cell versus single-cell micrometastases in pN0 early gastric cancer. J Surg Oncol 103:53–56CrossRefGoogle Scholar
  7. 7.
    Tanabe S, Hirabayashi S, Oda I, Ono H, Nashimoto A, Isobe Y, Miyashiro I, Tsujitani S, Seto Y, Fukagawa T, Nunobe S, Furukawa H, Kodera Y, Kaminishi M, Katai H (2017) Gastric cancer treated by endoscopic submucosal dissection or endoscopic mucosal resection in Japan from 2004 through 2006: JGCA nationwide registry conducted in 2013. Gastric Cancer 20:834–842.  https://doi.org/10.1007/s10120-017-0699-4 CrossRefGoogle Scholar
  8. 8.
    Suzuki H, Oda I, Abe S, Sekiguchi M, Mori G, Nonaka S, Yoshinaga S, Saito Y (2016) High rate of 5-year survival among patients with early gastric cancer undergoing curative endoscopic submucosal dissection. Gastric Cancer 19:198–205.  https://doi.org/10.1007/s10120-015-0469-0 CrossRefGoogle Scholar
  9. 9.
    Zeng Y-J, Zhang C-D, Dai D-Q (2015) Impact of lymph node micrometastasis on gastric carcinoma prognosis: a meta-analysis. World J Gastroenterol 21:1628–1635.  https://doi.org/10.3748/wjg.v21.i5.1628 CrossRefGoogle Scholar
  10. 10.
    Japanese Gastric Cancer Association (2017) Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer 20:1–19.  https://doi.org/10.1007/s10120-016-0622-4 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Kazuki Kanayama
    • 1
    • 2
  • Hiroshi Imai
    • 3
    Email author
  • Eri Usugi
    • 2
  • Taizo Shiraishi
    • 2
    • 4
  • Yoshifumi S. Hirokawa
    • 2
  • Masatoshi Watanabe
    • 2
  1. 1.Department of Clinical NutritionSuzuka University of Medical ScienceSuzukaJapan
  2. 2.Department of Oncologic PathologyMie University Graduate School of MedicineTsuJapan
  3. 3.Pathology DivisionMie University HospitalTsuJapan
  4. 4.Pathology DivisionKuwana City Medical CenterKuwanaJapan

Personalised recommendations